Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Pfizer

Status and phase

Terminated

Phase 2

Conditions

Aging

Frail Older Adults

Treatments

Drug: CP-424,391

Study type

Interventional

Funder types

Industry

Identifiers

NCT00527046

A257-102

Details and patient eligibility

About

A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.

Enrollment

396 patients

Sex

All

Ages

65 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

65-84 years old, BMI < 30, at risk for functional decline based on SF-36, Instrumental Activities of Daily Living (per Nagy's), or 2 or more falls in prior 2 years

Exclusion criteria

Significant history or symptoms of acute medical conditions, currently in an exercise program, pain or other conditions that would prevent participating in exercise testing